Penumbra, Inc. (PEN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Penumbra, Inc. (PEN) Healthcare & Pipeline Overview

Penumbra, Inc. is a medical device company focused on neurovascular and peripheral vascular therapies, offering innovative aspiration and embolization technologies. With a strong emphasis on stroke treatment and a global market presence, Penumbra distinguishes itself through its proprietary device designs and direct sales approach.

What Is the Investment Thesis for PEN?

The company's focus on aspiration-based thrombectomy systems and embolization technologies addresses critical unmet needs in stroke and vascular disease treatment. With a market capitalization of $12.5B and a P/E ratio of 79.95, Penumbra's valuation reflects its growth potential. A gross margin of 67.4% and a profit margin of 11.8% indicate strong profitability. Key growth catalysts include continued adoption of its Penumbra System for stroke intervention and expansion into new therapeutic areas. However, investors may want to evaluate potential risks such as competition from established medical device companies and regulatory hurdles.

Based on FMP financials and quantitative analysis

PEN Key Highlights

Market Cap of $12.5B reflects investor confidence in Penumbra's growth prospects within the medical device industry.

• P/E ratio of 79.95 indicates a premium valuation, suggesting high expectations for future earnings growth.
• Gross Margin of 67.4% demonstrates Penumbra's ability to maintain strong profitability in its product lines.
• Profit Margin of 11.8% showcases efficient operational management and cost control.
• Beta of 0.84 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.

Who Are PEN's Competitors?

PEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PEN's Key Strengths?

Innovative product portfolio in neurovascular and vascular intervention.

• Strong brand reputation and clinical evidence.
• Direct sales organization with deep customer relationships.
• High gross margins and profitability.

What Are PEN's Weaknesses?

Reliance on a limited number of key products.

• Exposure to regulatory risks and product recalls.
• Competition from larger medical device companies.
• High valuation relative to earnings.

What Could Drive PEN Stock Higher?

New product launches in neurovascular and peripheral vascular intervention.

• Continued adoption of the Penumbra System for stroke treatment.
• Expansion into new geographic markets.
• Positive clinical trial results for new products.

What Are the Key Risks for PEN?

Rich valuation — a P/E of 79.95 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Competition from established medical device companies.
• Regulatory risks and product recalls.
• Changes in reimbursement policies.
• Product liability claims.
• Technological obsolescence.

What Are the Growth Opportunities for PEN?

• Expansion of the Penumbra System for Stroke Intervention: The market for acute stroke treatment is substantial, driven by the high incidence of stroke and the need for rapid intervention. Penumbra's aspiration-based thrombectomy system offers a compelling solution for removing blood clots and restoring blood flow to the brain. Continued adoption of the Penumbra System in hospitals and stroke centers represents a significant growth opportunity. The global stroke management market is projected to reach $35 billion by 2028, providing a large addressable market for Penumbra.
• Growth in Peripheral Vascular Interventions: Penumbra's Indigo System addresses the growing need for effective thrombectomy solutions in peripheral arteries and veins. The increasing prevalence of peripheral artery disease (PAD) and venous thromboembolism (VTE) is driving demand for minimally invasive interventions. Penumbra's focus on aspiration-based thrombectomy offers a competitive advantage in this market. The peripheral vascular device market is expected to reach $15 billion by 2027, presenting a substantial growth opportunity for Penumbra.
• Development and Commercialization of New Products: Penumbra's commitment to innovation and product development is a key driver of growth. The company's pipeline includes new devices and technologies for neurovascular and peripheral vascular applications. Successful development and commercialization of these products will expand Penumbra's addressable market and strengthen its competitive position. Penumbra's investment in R&D is expected to yield new product launches in the coming years, contributing to revenue growth.
• Expansion into Immersive Therapeutics: Penumbra's Real Immersive System represents a new growth opportunity in the emerging field of immersive therapeutics. This technology has the potential to improve health, motor function, and cognition in patients with neurological disorders. The market for immersive therapeutics is growing rapidly, driven by increasing awareness of the benefits of virtual reality and augmented reality in healthcare. Penumbra's early entry into this market positions it to capitalize on this trend.
• Geographic Expansion: Penumbra's international presence is growing, with sales in Europe, Asia, and other regions. Expanding its geographic reach will allow Penumbra to access new markets and increase its revenue. The company's direct sales organization and distributor network provide a strong foundation for international expansion. Penumbra is targeting key international markets with high growth potential, such as China and India, to drive future revenue growth.

What Are PEN's Competitive Advantages?

• Proprietary technology in aspiration-based thrombectomy.
• Strong brand reputation in neurovascular intervention.
• Direct sales organization with deep customer relationships.
• Extensive patent portfolio protecting key products.
• High switching costs for hospitals and physicians due to training and experience.

What Does PEN Do?

Penumbra, Inc., founded in 2004 and headquartered in Alameda, California, is a global medical device company that designs, develops, manufactures, and markets innovative therapies and products focused on addressing challenging medical conditions and significant clinical needs. The company's initial focus was on neurovascular intervention, specifically stroke treatment, with its Penumbra System, an aspiration-based thrombectomy system designed to remove blood clots from the brain. Over time, Penumbra has expanded its product portfolio to include neurovascular embolization systems, such as the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil, used to treat aneurysms and other neurovascular lesions. Additionally, the company offers neurovascular access systems like Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM, facilitating access for various neurovascular therapies. Penumbra has also diversified into peripheral vascular interventions with its Indigo System, an aspiration-based thrombectomy system for removing clots from peripheral arteries and veins. The company's product offerings extend to neurosurgical aspiration tools (Artemis Neuro Evacuation Device), detachable embolic coil systems (Ruby Coil and Ruby LP), microcatheters (LANTERN), and occlusion devices (POD). More recently, Penumbra has ventured into immersive computer-based technologies and immersive therapeutics with its Real Immersive System, targeting health, motor function, and cognition. Penumbra distributes its products through a combination of direct sales organizations and distributors, serving hospitals and physicians worldwide.

What Products and Services Does PEN Offer?

• Designs and develops medical devices for neurovascular and vascular diseases.
• Manufactures aspiration-based thrombectomy systems for stroke treatment.
• Offers neurovascular embolization systems for treating aneurysms.
• Provides neurovascular access systems for intracranial access.
• Develops neurosurgical aspiration tools for tissue and fluid removal.
• Markets detachable embolic coil systems for peripheral embolization.
• Offers immersive computer-based technologies for therapeutic applications.

How Does PEN Make Money?

• Designs, develops, and manufactures medical devices in-house.
• Sells products through direct sales organizations and distributors.
• Generates revenue from the sale of aspiration-based thrombectomy systems.
• Revenue from neurovascular embolization systems and access systems.
• Recurring revenue from disposable components and accessories.

What Industry Does PEN Operate In?

Penumbra operates in the dynamic medical device industry, specifically within the neurovascular and peripheral vascular segments. The market for stroke treatment and vascular interventions is growing due to an aging population and increasing prevalence of vascular diseases. Competition includes established players like BAX: Baxter International Inc. and GMED: Globus Medical, Inc., as well as specialized companies focusing on thrombectomy and embolization technologies. Penumbra's innovative product portfolio and direct sales approach position it to capture market share in this competitive landscape.

Who Are PEN's Key Customers?

• Hospitals and stroke centers.
• Neurosurgeons and interventional radiologists.
• Vascular surgeons.
• Rehabilitation centers.

Over the past six months, Penumbra, Inc. insiders filed 3 SEC Form 4 transactions — 2 sales and 1 purchases. On net that is roughly 74K shares disposed (about $33K), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Penumbra, Inc.

Revenue for Penumbra, Inc. came in at $390.0M during Q2 FY2026, a 4.1% improvement versus the preceding quarter. The company recorded net income of $34.8M, with diluted EPS of $0.88. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, PEN averaged $1.02 in diluted EPS.

PEN Valuation & Market Position

With a $12.5B market cap, Penumbra, Inc. sits in the large-cap segment of the market. Analyst price targets span from $320.00 to $320.00, with a consensus of $320.00. At the current price of $317.78, that implies approximately 1% upside potential. Relative to its peer group, PEN's quantitative score of 94/100 is above the peer average of 69/100.

Return on equity for Penumbra, Inc. stands at 11.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.1%, showing how much profit it generates from its asset base. PEN trades at a trailing price-to-earnings ratio of 79.95, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.3%, the inverse of the P/E and a quick read on earnings relative to price.

Penumbra, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 19.01 places it in the safe zone, indicating low near-term bankruptcy risk.

Penumbra, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.8% above estimates on average.

Company Profile

Penumbra, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Alameda, US. The company is led by CEO Adam Elsesser. PEN has traded publicly since 2015.

PEN Financials

PEN Latest News

PEN Analyst Consensus

PEN MoonshotScore

Latest Penumbra, Inc. Analysis

What Investors Ask About Penumbra, Inc. (PEN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources